To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

March 26, 2019

Today's Rundown

Featured Story

Celgene refiles ozanimod with FDA 1 year after regulatory snafu

Celgene has refiled for FDA approval of ozanimod in multiple sclerosis. The resubmission comes one year after Celgene was rocked by a refusal-to-file notice from the FDA. 

Top Stories

iTeos brings on Sanofi cancer VP as CMO as it wades deeper into the clinic

Belgian immunotherapy developer iTeos Therapeutics has snagged Sanofi’s cancer drug development leader, Joanne Lager, M.D., to be its new chief medical officer.

After a delay, Can-Fite digs into subpopulation data as liver cancer drug fails to hit primary endpoint

Israeli biotech Can-Fite missed the primary endpoint in a midstage test of its experimental late-stage liver cancer drug namodenoson.

Aldeyra’s anti-allergy eyedrop sails through first phase 3 trial, boosting stock price by two-thirds

Aldeyra Therapeutics aced a phase 3 trial of reproxalap for allergic conjunctivitis, sending its stock up at least 66% in premarket trading.

Arch-backed Sana bags Harvard off-the-shelf cell therapy tech

Sana Biotechnology has licensed technology from Harvard University to further its efforts to develop off-the-shelf cell therapies. The goal is to genetically modify and differentiate stem cells to create cell therapies that are cloaked from the immune system.

Resources

[Whitepaper] Systolic Heart Failure: Real-World Study Using Electronic Health Records

Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care.

[Article] Are you ready for 2008 Microsoft SQL and Windows Servers end of life?

Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage.

[Whitepaper] Better Market Intelligence With Smart Search

From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve.

[Case Study] TriCore Reference Laboratories Transforms to Clinical Lab 2.0 Model

Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories.

[Whitepaper] Accelerating Clinical Trials through Access to Real-World Patient Data

Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs.

[Whitepaper] The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing

The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing.

[Whitepaper] How changes in drug substance processes can affect formulation

Download this whitepaper to learn more.

[Research] Maximize Pharma Marketing ROI with Digital HCP Engagement

Which HCP Touchpoints and channels are yielding the best results in today’s digital world?

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events